Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Michael Williams on Lenalidomide Plus Rituximab in First- Line MCL

March 19th 2016

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses frontline lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

Dr. Peter Martin on Future Treatment Approaches in Mantle Cell Lymphoma

March 15th 2016

Peter Martin, MD, associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, predicts future treatment approaches in the field of mantle cell lymphoma (MCL).

Frontline Lenalidomide/Rituximab Combo Highly Effective in MCL

November 4th 2015

The combination of lenalidomide and rituximab demonstrated an objective response rate of 92% as initial therapy for patients with mantle cell lymphoma.

MCL Patients Progressing on Ibrutinib Respond Poorly to Salvage Therapy

March 30th 2015

Patients with mantle cell lymphoma who develop ibrutinib resistance are unlikely to respond favorably to salvage chemotherapy.

Novel Agents, Combinations on Horizon for MCL

March 30th 2015

In an interview with OncLive, Bijal D. Shah, MD, discussed some new targeted agents for MCL and exactly how the treatment paradigm is poised to change for patients.

Dr. Bijal Shah on Bortezomib's Impact on Treatment of MCL

March 24th 2015

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the impact of the approval of frontline bortezomib for the treatment of mantle cell lymphoma (MCL).

Expert Discusses Frontline Bortezomib in MCL

March 18th 2015

To gain new insight on the phase III LYM-3002 study and bortezomib's use in the frontline MCL setting, OncLive interviewed Andrew Evens, DO, MSc, director of the Tufts Cancer Center and chief of the Division of Hematology/Oncology at Tufts University School of Medicine.

AbbVie Gains Ibrutinib Through Pharmacyclics Acquisition

March 5th 2015

AbbVie has announced plans to acquire the blockbuster BTK inhibitor ibrutinib, through a $21 billion acquisition of Pharmacyclics.

Dr. Jia Ruan Discusses Lenalidomide Plus Rituximab in MCL

December 9th 2014

Jia Ruan, MD, PhD, is an associate professor at Weill Cornell Medical College, discusses sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for MCL.

Dr. Goy Discusses Intensive Therapy for MCL

November 12th 2014

Andre Goy, MD, MS, discusses intensive therapy for the treatment of patients with mantle cell lymphoma (MCL).

European Commission Approves Ibrutinib for MCL, CLL

October 21st 2014

Ibrutinib has been approved by the European Commission for the treatment of adult patients with relapsed or refractory MCL and adult patients with CLL.

FDA Approves Bortezomib Regimen for Untreated MCL

October 9th 2014

The FDA has expanded the approval for bortezomib (Velcade) to include the frontline treatment of patients with mantle cell lymphoma.

Novel Rituximab Combinations Highly Effective in CLL

June 2nd 2014

The novel agents idelalisib and ABT-199 in combination with rituximab have demonstrated impressive activity with manageable toxicity for patients with relapsed or refractory chronic lymphocytic leukemia.

Dr. Byrd on Ibrutinib Versus Ofatumumab in CLL

June 1st 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising findings from the phase III RESONATE trial that compared ofatumumab to ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Ibrutinib Triples PFS, Doubles OS in Phase III CLL Trial

May 31st 2014

Treatment with single-agent ibrutinib dramatically increased PFS by nearly 80% and significantly extended OS by 57% compared with ofatumumab in patients with relapsed or refractory CLL.

Dr. Younes on the Implications of Ibrutinib's Approval for MCL

April 4th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the implications of ibrutinib's approval for patients with mantle cell lymphoma (MCL).